1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
OncoSil Medical Ltd

OncoSil Medical Ltd

AASX:OSL
0.79
AUD
-0.01
(-1.25%)
-0.48EPS
21.93MMarket Cap
Mar 02Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
0.08
0.09
0.12
0.09
0.11
0.07
Basic EPS, GAAP
-2.54
-2.39
-3.64
-4.41
-4.9
-4.03
-1.96
-3.85
-4.04
-3.77
-2.22
-1.37
-0.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.12
5.78
9.43
6.15
8.6
5
7.97
4.42
3.44
1.88
0.55
0.22
0.16
Tangible Book Value per Share
7.92
5.78
9.43
6.15
8.6
5
7.97
4.42
3.44
1.88
0.55
0.22
0.16
Basic Weighted Avg Shares
2
1
1
2
2
2
2
3
3
3
6
11
23
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-5,543.68
-4,977.04
-3,462.12
-2,531.19
-1,322.94
-859.17
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-3
-5
-7
-9
-9
-4
-10
-11
-11
-12
-15
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-4,896.76
-4,627.79
-3,085.02
-2,395.37
-1,289.71
-644.53
Working Capital
9
7
15
10
18
11
22
11
11
10
5
3
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
12
7
15
10
18
11
22
12
11
10
5
3
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-46.31
-30.11
-43.8
-56.25
-60.37
-59.43
-26.17
-62.11
-93.85
-107.81
-171.01
-392.41
-268.15

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.39%
-8.2%
60.99%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
17.53%
2.32%
-28.08%
Sales/Revenue/Turnover
- -
55.69%
43.92%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
2

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.22
2025
- -
- -
-1.37
2026
- -
- -
-0.48

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nigel Lange
Full Time Employees
6
Sector
Health technology
Industry
Medical specialties
Address
7 Eden Park Drive Macquarie Park NSW Australia 2113
IPO Date
Jul 11, 2005
Website
oncosil.com.au
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
OncoSil Medical Limited OncoSil Medical Limited is an Australia-based medical device company that develops and commercializes localized radiation therapy devices for the treatment of unresectable locally advanced pancreatic cancer and distal cholangiocarcinoma. The company's lead product, OncoSil, is a single-use brachytherapy device comprising radioactive Phosphorous-32 microparticles delivered via endoscopic ultrasound guidance directly into tumors in combination with gemcitabine-based chemotherapy to induce prolonged local tumor control and size reduction; it targets patients ineligible for surgery due to tumor proximity to vital structures. Founded in 2005 and headquartered in Macquarie Park, New South Wales, the company operates globally from offices in Australia and Germany, with distribution access to 11 markets including Europe, the GCC region, Egypt, and Nordic countries; it serves interventional oncologists and healthcare providers focused on pancreatic cancer treatment. Recent developments include strategic distribution agreements in the GCC, Egypt, and Nordic regions in late 2024, alongside key regulatory approvals enhancing market access; in September 2025, OncoSil announced a cooperation with Pancreatic Cancer Europe to advance treatment opportunities, raise awareness of therapy disparities, and promote innovative solutions across the continent; the company also completed a Share Purchase Plan in July 2025 to support commercialization efforts.

Company News

Company News APIChatGPT

  • proactiveinvestors.com

    Ferrari gets Jefferies backing as classic car auction prices surge

  • proactiveinvestors.com

    Inside Biotech: OncoSil’s TGA breakthrough puts focus back on pancreatic cancer challenge

  • proactiveinvestors.com

    FTSE 100 Live: Stocks off to tired start, ConvaTec and Mitchells & Butlers drop